2017 has clearly brought many changes in our world, both internal and external to CARRA. Time will tell what the impact of political and economic forces will be on our organization, but there is one certainty: CARRA must prepare to be able to withstand the many challenges that we are likely to face in the next few years to continue and build on the progress and momentum that we have all worked to create in the last few years.
CARRA has enjoyed astounding growth and change in the last few years (http://www.the-rheumatologist.org/article/future-pediatric-rheumatology-grounded-evolution-childhood-arthritis-rheumatology-research-alliance/). Now more than ever, we must focus and align our collective energy with CARRA’s mission, core values and operating principles. This means we have to work together to build unity and consensus around our research strategies, more clearly define and standardize processes and procedures, and maintain the transparency and democratic principles upon which CARRA was founded.
Nominations are due Tuesday, August 29, 2017
Applications are due Tuesday, September 5, 2017
CARRA is seeking reviewers to serve on CARRA’s Grant Scientific Review Committee (SRC). Committee members will be responsible for reviewing CARRA’s internal Small, Large and Fellow Small grants. The term of appointment is 3 years, renewable. Senior and novice reviewers are encouraged to apply (fellows are not eligible). We are also seeking one individual to serve as committee chair.
Nominations are due: September 1
Applications are due: September 14
The CARRA Elections Committee is seeking nominations for the Ethics Committee (5 open positions). You may nominate yourself or someone else by September 1.
CARRA is pleased to announce CARRA Large (up to $50k) and Small (up to $25k) Grant Applications Due 10/1/17.
The Childhood Arthritis and Rheumatology Research Alliance (CARRA), Inc. announced today that the first two patients had enrolled in the Start Time Optimization in Polyarticular Juvenile Idiopathic Arthritis (STOP-JIA) project. STOP-JIA aims to answer a critical question facing patients and doctors: “When is the best time to start biologic medications in polyarticular JIA?”
As of June 2017, there are 555 members and 119 sites in the United States and Canada.
The below chart shows the growth of CARRA from 2003 to 2016:
We are very excited to announce that CARRA had a record year for membership growth! We had 125 new members join in 2016, bringing our current membership total to...
Brian Feldman, MD, MSc, FRCPC
University of Toronto – The Hospital for Sick Children
I know that the rheumatology service isn’t involved in the treatment of most Kawasaki Disease patients at many centres. At SickKids, though, we are. Our team sees somewhere around 150 patients with KD a year.
I hear commonly, mostly from fellows who join us from other centres, that when it comes to KD, the faculty at SickKids tends to err on the side of over-treatment. How can one over-treat a condition for which randomized trials clearly indicate an important benefit of treatment? The newly arrived fellows imply that we over-diagnose.